Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice

@article{Reid2003SingledosePO,
  title={Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice},
  author={Joel M. Reid and David P. Squillace and Matthew Ames},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2003},
  volume={51},
  pages={483-487}
}
NLCQ-1 (NSC 709257) is a weak DNA-binding bioreductive antiproliferative agent, with potent in vitro antiproliferative activity against rodent and human tumor cell lines under aerobic and anaerobic conditions. Interest in this quinoline analog is based in part on its in vivo synergistic antitumor effect with radiotherapy or chemotherapy against mouse tumors and human xenografts. A sensitive, specific HPLC method was developed to measure NLCQ-1 in biological fluids. Calibration curves were… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Mitomycin C: a clinical update.

Cancer treatment reviews • 2001
View 1 Excerpt

Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study.

International journal of radiation oncology, biology, physics • 1998
View 1 Excerpt

Similar Papers

Loading similar papers…